Peripheral Artery Disease on The Prognosis Value of Patients with Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Retrospective, Single-Center Cohort Study
PAD on the prognosis value of patients with CAD undergoing PCI.
DOI:
https://doi.org/10.1532/hsf.4211Keywords:
PAD; CAD, PCI; prognosis value.Abstract
Objective: The purpose of this investigation aimed to clarify the impact of peripheral artery disease (PAD) on the prognosis value of patients with stable coronary artery disease (CAD) who underwent percutaneous coronary intervention (PCI).
Methods: The SPSS 16 software was used for secondary analysis of DRYAD database data. A total of 204 patients were enrolled from Shinonoi General Hospital for newly diagnosed stable CAD and received PCI performance between October 2014 and October 2017. Patients with old myocardial infarction (MI) were excluded. We divided patients into two groups with PAD and without PAD. The primary endpoints were major adverse cardiac events (MACE, defined as all-cause death, non-fatal MI, and non-fatal stroke) and cardiovascular events (defined as cardiovascular death, non-fatal MI, and non-fatal stroke). The secondary outcomes were the individual components of the composite primary outcomes. The median follow-up time was 783 days.
Results: No statistical difference was found between PAD and non-PAD patients of lesional characteristics. Spearman’s rank correlations indicate diabetes mellitus (DM) (P = 0.019) and HbA1c (P = 0.009) are positively correlated with PAD. In Kaplan-Meier analysis, patients with PAD predicted poor prognosis in MACE (P < 0.05) and cardiovascular events (P < 0.05). In Multivariable Cox proportional hazards analysis, patients with PAD independently predicted MACE and cardiovascular events.
Conclusions: PAD is a significant mediator for the prognosis of patients with stable CAD who underwent PCI treatment.
References
Abola MTB, Golledge J, Miyata T, et al. 2020. Asia-Pacific Consensus Statement on the Management of Peripheral Artery Disease: A Report from the Asian Pacific Society of Atherosclerosis and Vascular Disease Asia-Pacific Peripheral Artery Disease Consensus Statement Project Committee. J Atheroscler Thromb. 27(8):809-907.
Bhatt DL, Steg PG, Ohman EM, et al. 2006. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. Journal of the American Medical Association. 295(2):180–189.
Chiu JH, Topol EJ, Whitlow PL, et al. 2003. Peripheral vascular disease and one-year mortality following percutaneous coronary revascularization
Am J Cardiol. 92:582-583.
Fowkes FG, Rudan D, Rudan I, et al. 2013. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 382(9901):1329‐1340.
Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016[J]. 2017. Lancet. 390(10100):1211-1259.
McKenna M, Wolfson S, Kuller L. 1991. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis. 87: 119-128.
Morris DR, Rodriguez AJ, Golledge J. 2014. Association of Lower Extremity Performance with Cardiovascular and All-Cause Mortality in Patients with Peripheral Artery Disease: A Systematic Review and Meta-analysis. J Am Heart Assoc. 3: e001-105.
Nikolsky E, Mehran R, Mintz GS, et al. 2004. Impact of symptomatic peripheral arterial disease on 1-year mortality in patients undergoing percutaneous coronary interventions.J Endovasc Ther. 11:60-70.
Nishijima A, Yamamoto N, Yoshida R, Hozawa K, Yanagibayashi S, et al. 2017. Coronary Artery Disease in Patients with Critical Limb Ischemia Undergoing Major Amputation or Not. Plast Reconstr Surg Glob Open. 5: e1377.
Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes
FG, et al. 2007. TA SC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc
Surg. 33(Suppl 1): S1–75.
O’Connor GT, Malenka DJ, Quinton H, et al. for the Northern New England Cardiovascular Disease Study Group. 1999. Multivariate prediction of in-hospital mortality after percutaneous coronary interventions in 1994–1996. J Am Coll Cardiol. 34:681–91.
Olin JW, Allie DE, Belkin M, et al. 2010. CCF/AHA/ACR/SCAI/SIR/SVM/SVN/SVS 2010 performance measures for adults with peripheral artery disease. Vasc Med. 15(6):481-512.
Olinic DM, Spinu M, Olinic M, Homorodean C, Tataru DA, Liew A, Schernthaner GH, Stanek A, Fowkes G, Catalano M. 2018. Epidemiology of peripheral artery disease in Europe: VAS Educational Paper. Int Angiol. 37(4):327-334.
Roth GA, Johnson C, Abajobir A, et al. 2017. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015[J]. Journal of the American College of Cardiology. 70(1):1-25.
Ryu HM, Kim JS, Ko YG, Hong MK, Jang Y, et al. 2012. Clinical outcomes of infrapopliteal angioplasty in patients with critical limb ischemia. Korean Circ J. 42: 259–265.
Saw J, Bhatt DL, Moliterno DJ, Brener SJ, Steinhubl SR, Lincoff AM, Tcheng JE, Harrington RA, Simoons M, Hu T, Sheikh MA, Kereiakes DJ, Topol EJ. 2006. The influence of peripheral arterial disease on outcomes: a pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials. J Am Coll Cardiol. 48(8):1567-72.
Singh M, Lennon R, Darbar D, et al. 2004. Effect of peripheral arterial disease in patients undergoing percutaneous coronary intervention with intracoronary stents. Mayo Clin Proc. 79:1113-1118.
Suzuki S, Hashizume N, Kanzaki Y, Maruyama T, Kozuka A, Yahikozawa K. 2019. Prognostic significance of serum albumin in patients with stable coronary artery disease treated by percutaneous coronary intervention. PLoS One. 14(7): e0219044.
